PART I FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The unaudited condensed consolidated financial statements provide a snapshot of the company's financial position and performance [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) | Metric | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :----------------------------- | :----------------------------- | :------------------------------- | | Total Assets | $86,699 | $117,691 | | Total Liabilities | $45,443 | $46,056 | | Total Stockholders' Equity | $41,256 | $71,635 | | Cash and cash equivalents | $41,214 | $39,019 | | Marketable securities | $25,771 | $58,776 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Three Months Ended June 30 | Metric | 2025 (in thousands) | 2024 (in thousands) | Change (in thousands) | | :--------------------------- | :------------------ | :------------------ | :-------------------- | | Research and development | $17,410 | $15,540 | $1,870 | | General and administrative | $10,081 | $6,938 | $3,143 | | Total operating expenses | $27,491 | $22,478 | $5,013 | | Loss from operations | $(27,491) | $(22,478) | $(5,013) | | Interest income, net | $836 | $1,254 | $(418) | | Net loss | $(26,663) | $(21,227) | $(5,436) | | Net loss per share (basic & diluted) | $(0.56) | $(0.52) | $(0.04) | Six Months Ended June 30 | Metric | 2025 (in thousands) | 2024 (in thousands) | Change (in thousands) | | :--------------------------- | :------------------ | :------------------ | :-------------------- | | Research and development | $33,921 | $29,866 | $4,055 | | General and administrative | $17,039 | $14,027 | $3,012 | | Total operating expenses | $50,960 | $43,893 | $7,067 | | Loss from operations | $(50,960) | $(43,893) | $(7,067) | | Interest income, net | $1,896 | $2,731 | $(835) | | Net loss | $(49,076) | $(41,167) | $(7,909) | | Net loss per share (basic & diluted) | $(1.05) | $(1.02) | $(0.03) | [Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Stockholders' Equity Changes (in thousands) | Metric | December 31, 2024 | June 30, 2025 | | :-------------------------- | :---------------- | :------------ | | Common Stock | $4 | $5 | | Additional Paid-in Capital | $378,632 | $397,354 | | Accumulated Other Comp. Income (Loss) | $27 | $1 | | Accumulated Deficit | $(307,028) | $(356,104) | | **Total Stockholders' Equity** | **$71,635** | **$41,256** | - Additional paid-in capital increased by **$13,266 thousand** from issuance of common stock and **$5,183 thousand** from stock-based compensation during the six months ended June 30, 2025[23](index=23&type=chunk) - Accumulated deficit increased by **$49,076 thousand** due to net loss for the six months ended June 30, 2025[23](index=23&type=chunk)[21](index=21&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flows (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :---------------------------------- | :----- | :----- | | Net cash used in operating activities | $(44,372) | $(37,383) | | Net cash provided by investing activities | $33,027 | $17,510 | | Net cash provided by financing activities | $13,540 | $5,193 | | Net change in cash and cash equivalents | $2,195 | $(14,680) | | Cash, cash equivalents and restricted cash at end of period | $42,141 | $38,239 | - Operating activities primarily used cash due to net losses, partially offset by non-cash expenses like stock-based compensation[145](index=145&type=chunk)[146](index=146&type=chunk) - Investing activities provided cash mainly from proceeds from sales and maturities of marketable securities[147](index=147&type=chunk)[148](index=148&type=chunk) - Financing activities provided cash from the issuance of common stock (ATM facility) and stock option exercises[149](index=149&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) [1. Nature of the Business and Basis of Presentation](index=9&type=section&id=1.%20Nature%20of%20the%20Business%20and%20Basis%20of%20Presentation) - Vigil Neuroscience, Inc is a clinical-stage biotechnology company focused on developing disease-modifying therapeutics for rare and common neurodegenerative diseases by restoring microglia function[29](index=29&type=chunk)[104](index=104&type=chunk) - The company entered into a Merger Agreement with Sanofi on May 21, 2025, for Sanofi to acquire Vigil for **$8.00 per share in cash** plus a **$2.00 Contingent Value Right (CVR)** per share, contingent on the first commercial sale of VG-3927[31](index=31&type=chunk)[105](index=105&type=chunk) - The rights to iluzanebart (VGL101) will be returned to Amgen Inc, the original licensor, prior to the closing of the Merger[34](index=34&type=chunk)[105](index=105&type=chunk) - As of June 30, 2025, the company had an **accumulated deficit of $356.1 million** and has incurred recurring losses since inception, leading to **substantial doubt about its ability to continue as a going concern**[41](index=41&type=chunk)[44](index=44&type=chunk)[111](index=111&type=chunk) - During the six months ended June 30, 2025, the company sold 5,784,772 shares of common stock under its ATM facility for **net proceeds of $13.3 million**[42](index=42&type=chunk)[82](index=82&type=chunk) [2. Summary of Significant Accounting Policies](index=17&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) - The preparation of financial statements requires management to make significant estimates and assumptions, particularly for research and development expenses, prepaid/accrued costs, and stock-based compensation[51](index=51&type=chunk) - Cash equivalents primarily consist of money market funds and government securities, while marketable securities are classified as available-for-sale and reported at fair value[52](index=52&type=chunk)[54](index=54&type=chunk) - The company adopted ASU No 2023-07 (Segment Reporting) as of January 1, 2024, resulting in additional segment reporting disclosures[60](index=60&type=chunk) [3. Fair Value Measurements and Financial Instruments](index=19&type=section&id=3.%20Fair%20Value%20Measurements%20and%20Financial%20Instruments) Fair Value Measurement at June 30, 2025 (in thousands) | Asset Category | Level 1 | Level 2 | Level 3 | Total | | :------------- | :------ | :------ | :------ | :---- | | Cash equivalents | $29,733 | $— | $— | $29,733 | | Marketable securities | $— | $25,771 | $— | $25,771 | | Restricted cash | $927 | $— | $— | $927 | | **Total** | **$30,660** | **$25,771** | **$—** | **$56,431** | - As of June 30, 2025, the company held 13 marketable securities, with 6 in an unrealized loss position, totaling **$(4) thousand in gross unrealized losses**[62](index=62&type=chunk)[63](index=63&type=chunk) [4. Prepaid Expenses and Other Current Assets](index=20&type=section&id=4.%20Prepaid%20Expenses%20and%20Other%20Current%20Assets) Prepaid Expenses and Other Current Assets (in thousands) | Category | June 30, 2025 | December 31, 2024 | | :-------------------------- | :-------------- | :---------------- | | Research and development | $1,239 | $1,231 | | Business insurance | $509 | $113 | | Other receivables | $347 | $228 | | Interest receivable | $211 | $371 | | Other | $1,002 | $846 | | **Total** | **$3,308** | **$2,789** | [5. Accrued Expenses and Other Current Liabilities](index=20&type=section&id=5.%20Accrued%20Expenses%20and%20Other%20Current%20Liabilities) Accrued Expenses and Other Current Liabilities (in thousands) | Category | June 30, 2025 | December 31, 2024 | | :-------------------------- | :-------------- | :---------------- | | Research and development | $4,636 | $5,734 | | Merger-related costs | $3,272 | $— | | Payroll and employee related | $2,603 | $4,402 | | Professional fees | $763 | $710 | | Other | $172 | $289 | | **Total** | **$11,446** | **$11,135** | [6. Stock-Based Compensation](index=20&type=section&id=6.%20Stock-Based%20Compensation) - The 2021 Stock Option and Incentive Plan's evergreen provision increased shares reserved for future grants by **2,044,338 on January 1, 2025**[67](index=67&type=chunk) - A one-time stock option repricing occurred on May 3, 2024, for options with an exercise price greater than $3.03 per share, repricing them to $3.03 per share, resulting in **$0.8 million in incremental stock-based compensation expense**[70](index=70&type=chunk)[71](index=71&type=chunk) Stock-Based Compensation Expense (in thousands) | Category | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------- | :----------------------------- | :----------------------------- | | Research and development | $1,927 | $1,716 | | General and administrative | $3,256 | $3,300 | | **Total** | **$5,183** | **$5,016** | - As of June 30, 2025, there was approximately **$14.1 million in unrecognized stock-based compensation expense** related to unvested options and **$0.2 million** for unvested RSUs[72](index=72&type=chunk) [7. Preferred Stock](index=21&type=section&id=7.%20Preferred%20Stock) - On July 1, 2024, the company issued 537,634 shares of Series A non-voting convertible preferred stock to Sanofi for **net proceeds of $39.6 million**[43](index=43&type=chunk)[73](index=73&type=chunk)[78](index=78&type=chunk) - In connection with the SPA, the company granted Genzyme Corporation (a Sanofi subsidiary) an exclusive Right of First Negotiation (ROFN) for its small molecule TREM2 agonist program, including VG-3927[73](index=73&type=chunk) - Holders of Series A preferred stock do not have voting rights but are entitled to receive dividends on an as-if-converted basis[76](index=76&type=chunk)[77](index=77&type=chunk) [8. Common Stock](index=23&type=section&id=8.%20Common%20Stock) - During the six months ended June 30, 2025, the company sold **5,784,772 shares** of common stock under its At-the-Market (ATM) facility for **net proceeds of $13.3 million**[82](index=82&type=chunk) - All pre-funded warrants to purchase 2,980,889 shares of common stock were exercised as of June 30, 2025[83](index=83&type=chunk) Common Stock Reserved for Future Issuance (Shares) | Category | June 30, 2025 | December 31, 2024 | | :---------------------------------- | :------------ | :---------------- | | Common stock options | 9,301,334 | 7,500,591 | | Restricted Stock Units | 35,000 | — | | Series A convertible preferred stock | 5,376,340 | 5,376,340 | | Pre-funded warrants | — | 926,094 | | Shares available for 2021 Plan | 2,368,584 | 2,248,964 | | Shares available for 2021 ESPP | 572,254 | 572,254 | | **Total** | **17,653,512**| **16,624,243** | [9. Net Loss per Share](index=25&type=section&id=9.%20Net%20Loss%20per%20Share) Net Loss per Share Attributable to Common Stockholders (Basic and Diluted) | Period | 2025 | 2024 | | :-------------------------- | :----- | :----- | | Three Months Ended June 30 | $(0.56) | $(0.52) | | Six Months Ended June 30 | $(1.05) | $(1.02) | - Potentially dilutive securities were excluded from the computation of diluted net loss per common share as their effect would be anti-dilutive[87](index=87&type=chunk) [10. Leases](index=25&type=section&id=10.%20Leases) - The company has an operating lease for laboratory and office space in Watertown, MA, with a weighted-average remaining lease term of **7.4 years** as of June 30, 2025[88](index=88&type=chunk)[90](index=90&type=chunk) Operating Lease Expense (in thousands) | Period | 2025 | 2024 | | :-------------------------- | :----- | :----- | | Three Months Ended June 30 | $0.6 | $0.6 | | Six Months Ended June 30 | $1.2 | $1.2 | Future Minimum Lease Payments (as of June 30, 2025, in thousands) | Year | Operating Leases | | :--- | :--------------- | | 2025 | $984 | | 2026 | $2,027 | | 2027 | $2,088 | | 2028 and thereafter | $11,269 | | **Total lease payments** | **$16,368** | | Less: imputed interest | $(3,931) | | **Total future minimum lease payments** | **$12,437** | [11. Commitments and Contingencies](index=26&type=section&id=11.%20Commitments%20and%20Contingencies) - A **$20.0 million contract liability** was recognized on July 1, 2024, related to Sanofi's Right of First Negotiation (ROFN) for the small molecule TREM2 agonist program (VG-3927)[94](index=94&type=chunk) - The company contributed **$0.5 million** to its 401(k) Plan during the six months ended June 30, 2025[97](index=97&type=chunk) - The company is not currently a party to any material legal proceedings[99](index=99&type=chunk) [12. Segment Reporting](index=27&type=section&id=12.%20Segment%20Reporting) - The company operates as a single operating segment, with all assets located in the United States and no revenue generated through June 30, 2025[100](index=100&type=chunk) Significant Segment Expenses (Six Months Ended June 30, 2025, in thousands) | Expense Category | Amount | | :---------------------------------- | :----- | | Iluzanebart external R&D | $9,375 | | Small molecule TREM2 external R&D | $7,636 | | Other external R&D | $3,613 | | General and administrative external | $7,770 | | Facilities, personnel-related, and other | $22,566 | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the Sanofi merger, program updates, financial results, and the ongoing need for substantial additional funding - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing microglia-targeted therapies for neurodegenerative diseases[104](index=104&type=chunk) - The company entered into a definitive merger agreement with Sanofi on May 21, 2025, for an acquisition price of **$8.00 per share in cash plus a $2.00 CVR per share**[105](index=105&type=chunk) - The Phase 2 IGNITE clinical trial for iluzanebart in ALSP patients **showed no beneficial effects**, leading to the discontinuation of the program[106](index=106&type=chunk)[105](index=105&type=chunk) - Phase 1 clinical trial data for VG-3927 demonstrated a favorable safety profile and a **robust, dose-dependent reduction of sTREM2 (up to ~50%)** in CSF[107](index=107&type=chunk)[108](index=108&type=chunk) - As of June 30, 2025, the company had **$67.0 million in cash, cash equivalents, and marketable securities**, and an **accumulated deficit of $356.1 million**[110](index=110&type=chunk)[111](index=111&type=chunk)[113](index=113&type=chunk)[152](index=152&type=chunk)[156](index=156&type=chunk) [Components of Our Results of Operations](index=32&type=section&id=Components%20of%20Our%20Results%20of%20Operations) - Operating expenses consist solely of research and development (R&D) and general and administrative (G&A) expenses[118](index=118&type=chunk) - R&D expenses are expensed as incurred and include costs for discovery, preclinical/clinical development, and manufacturing, while G&A expenses cover personnel, corporate facilities, and professional fees[120](index=120&type=chunk)[123](index=123&type=chunk)[127](index=127&type=chunk) - Interest income, net, is primarily derived from cash, cash equivalents, and marketable securities[129](index=129&type=chunk) [Results of Operations](index=35&type=section&id=Results%20of%20Operations) Three Months Ended June 30, 2025 vs. 2024 (in thousands) | Metric | 2025 | 2024 | Change | | :--------------------------- | :----- | :----- | :----- | | Research and development | $17,410 | $15,540 | $1,870 | | General and administrative | $10,081 | $6,938 | $3,143 | | Total operating expenses | $27,491 | $22,478 | $5,013 | | Net loss | $(26,663) | $(21,227) | $(5,436) | | Interest income, net | $836 | $1,254 | $(418) | Six Months Ended June 30, 2025 vs. 2024 (in thousands) | Metric | 2025 | 2024 | Change | | :--------------------------- | :----- | :----- | :----- | | Research and development | $33,921 | $29,866 | $4,055 | | General and administrative | $17,039 | $14,027 | $3,012 | | Total operating expenses | $50,960 | $43,893 | $7,067 | | Net loss | $(49,076) | $(41,167) | $(7,909) | | Interest income, net | $1,896 | $2,731 | $(835) | - The increase in R&D expenses for the six months ended June 30, 2025, was primarily due to **$2.0 million in iluzanebart expenses** and **$1.7 million in personnel-related expenses**[136](index=136&type=chunk)[137](index=137&type=chunk)[138](index=138&type=chunk) - The increase in G&A expenses for both periods was primarily related to increased legal and professional fees associated with the **proposed merger with Sanofi**[133](index=133&type=chunk)[139](index=139&type=chunk) [Liquidity and Capital Resources](index=37&type=section&id=Liquidity%20and%20Capital%20Resources) - Since inception through June 30, 2025, the company has raised approximately **$376.5 million in gross proceeds** primarily from equity offerings[141](index=141&type=chunk) - As of June 30, 2025, cash, cash equivalents, and marketable securities totaled **$67.0 million**[141](index=141&type=chunk) Cash Flow Summary (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :---------------------------------- | :----- | :----- | | Net cash used in operating activities | $(44,372) | $(37,383) | | Net cash provided by investing activities | $33,027 | $17,510 | | Net cash provided by financing activities | $13,540 | $5,193 | | Net increase in cash, cash equivalents and restricted cash | $2,195 | $(14,680) | - The company expects its existing cash, cash equivalents, and marketable securities to **fund operations into 2026**, after which substantial additional funding will be required[156](index=156&type=chunk) [Critical Accounting Policies and Significant Judgments and Estimates](index=40&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgments%20and%20Estimates) - There have been no material changes to the significant accounting policies previously disclosed in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024[159](index=159&type=chunk) [Emerging Growth Company Status](index=42&type=section&id=Emerging%20Growth%20Company%20Status) - The company qualifies as an 'emerging growth company' and has elected to use the extended transition period for complying with new or revised financial accounting standards[161](index=161&type=chunk)[401](index=401&type=chunk)[402](index=402&type=chunk) [Recently Issued Accounting Pronouncements](index=42&type=section&id=Recently%20Issued%20Accounting%20Pronouncements) - There have been no other material changes to the significant accounting policies previously disclosed in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024[162](index=162&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not applicable as the company has elected scaled disclosure requirements available to Smaller Reporting Companies - The company is electing scaled disclosure requirements available to Smaller Reporting Companies, making this item not applicable[163](index=163&type=chunk) [Item 4. Controls and Procedures](index=42&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2025 - Management, with the participation of the CEO and CFO, evaluated the effectiveness of disclosure controls and procedures and concluded they were **effective at the reasonable assurance level** as of June 30, 2025[165](index=165&type=chunk) - There were **no changes in internal control over financial reporting** during the three months ended June 30, 2025, that materially affected, or are reasonably likely to materially affect, internal control over financial reporting[166](index=166&type=chunk) PART II OTHER INFORMATION [Item 1. Legal Proceedings](index=32&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - The company is not currently a party to any litigation or legal proceedings that, in the opinion of management, are probable to have a material adverse effect on its business[168](index=168&type=chunk) [Item 1A. Risk Factors](index=32&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks related to the Sanofi merger, its financial position, product development, and regulatory hurdles - Risks related to the proposed merger with Sanofi include the **possibility of non-completion**, adverse effects on stock price and business if the merger fails, and business uncertainties during the pending period[170](index=170&type=chunk)[171](index=171&type=chunk)[172](index=172&type=chunk)[174](index=174&type=chunk)[176](index=176&type=chunk)[177](index=177&type=chunk) - The company has a limited operating history, has incurred significant operating losses since inception (**accumulated deficit of $356.1 million**), and will require additional financing, raising **substantial doubt about its ability to continue as a going concern**[180](index=180&type=chunk)[181](index=181&type=chunk)[185](index=185&type=chunk) - Development efforts are early-stage, highly dependent on the clinical advancement of VG-3927, and face risks of delays and extensive regulatory hurdles, as demonstrated by the **discontinuation of the iluzanebart Phase 2 trial**[106](index=106&type=chunk)[205](index=205&type=chunk)[212](index=212&type=chunk)[219](index=219&type=chunk)[224](index=224&type=chunk)[231](index=231&type=chunk)[236](index=236&type=chunk) - The company **relies heavily on third parties** for product manufacturing, research, and clinical testing, and is dependent on single-source suppliers, which could lead to disruptions[270](index=270&type=chunk)[279](index=279&type=chunk)[280](index=280&type=chunk) - Intellectual property risks include the **inability to obtain and maintain broad patent protection**, challenges to inventorship or ownership, and potential claims of infringement from third parties[287](index=287&type=chunk)[295](index=295&type=chunk)[319](index=319&type=chunk) - The company is subject to **extensive and ongoing government regulation**, including post-approval requirements, potential healthcare legislative reforms, and compliance with anti-kickback laws[236](index=236&type=chunk)[350](index=350&type=chunk)[356](index=356&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=82&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This item is not applicable to the company for the reported period - Not applicable[433](index=433&type=chunk) [Item 3. Defaults Upon Senior Securities](index=82&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This item is not applicable to the company for the reported period - Not applicable[434](index=434&type=chunk) [Item 4. Mine Safety Disclosures](index=83&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company for the reported period - Not applicable[435](index=435&type=chunk) [Item 5. Other Information](index=83&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated a Rule 10b5-1 trading plan during the fiscal quarter ended June 30, 2025 - None of the company's directors or officers adopted or terminated a Rule 10b5-1 trading plan or arrangement during the fiscal quarter ended June 30, 2025[436](index=436&type=chunk) [Item 6. Exhibits](index=84&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed as part of the Quarterly Report on Form 10-Q - Key exhibits include the Agreement and Plan of Merger with Sanofi (May 21, 2025), corporate organizational documents, and certifications of the Principal Executive and Financial Officers[440](index=440&type=chunk) [Signatures](index=85&type=section&id=Signatures) - The report was signed on August 5, 2025, by Ivana Magovčević-Liebisch, President and Chief Executive Officer, and Jennifer Ziolkowski, Chief Financial Officer[444](index=444&type=chunk)

分组1 - Vigil Neuroscience, Inc. (VIGL) closed at $7.93, with a 0.6% gain over the past four weeks, and a mean price target of $10 indicates a 26.1% upside potential [1] - The average price targets from analysts range from a low of $8.00 to a high of $22.00, with a standard deviation of $5.29, suggesting variability in estimates [2] - Analysts show strong agreement on VIGL's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] 分组2 - Recent revisions in earnings estimates for VIGL have been positive, with one estimate moving higher and the Zacks Consensus Estimate increasing by 2.6% [12] - VIGL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Group 1 - Halper Sadeh LLC is investigating TuHURA Biosciences, Inc. (NASDAQ: HURA) for potential violations related to its merger with Kineta, Inc. [1] - Vigil Neuroscience, Inc. (NASDAQ: VIGL) is under scrutiny due to its sale to Sanofi, where shareholders will receive $8.00 per share in cash and a contingent value right for an additional $2.00 per share based on the commercial sale of VG-3927 [1] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [2] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no cost [3] - The firm represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [3]

Core Viewpoint - Vigil Neuroscience, Inc. (VIGL) has seen a significant stock price increase of 225.6% over the past four weeks, with a mean price target of $10 indicating a further upside potential of 26.9% [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $5.29, indicating variability among analysts; the lowest estimate suggests a 1.5% increase to $8, while the highest predicts a surge of 179.2% to $22 [2] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases; the Zacks Consensus Estimate for the current year has risen by 7.3% over the past month with three estimates increasing and no negative revisions [11][12] - VIGL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a solid potential upside [13]

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the proposed buyout of Vigil Neuroscience, Inc. by Sanofi, focusing on whether shareholders are receiving adequate compensation for their shares [1][3]. Buyout Details - Vigil Neuroscience has agreed to be acquired by Sanofi for an upfront price of $8.00 per share in cash, along with a contingent value right (CVR) worth an additional $2.00 upon achieving certain milestones [2]. - Following the transaction, Vigil's shares will no longer be publicly traded, and shareholders will be cashed out of their investment positions [2]. Investigation Focus - The investigation aims to determine if Vigil's investors are receiving sufficient monetary consideration and whether the company's officers or directors breached fiduciary duties or violated securities laws in agreeing to the buyout price [3]. - Analysts had set price targets for Vigil's shares exceeding $13.00 at the time of the announcement, raising questions about the adequacy of the buyout offer [3].

Core Insights - Vigil Neuroscience, Inc. announced an update on the Phase 2 IGNITE clinical trial for iluzanebart, a monoclonal antibody TREM2 agonist, aimed at treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) [1][2] Group 1: Clinical Trial Results - Iluzanebart showed a favorable safety, tolerability, and pharmacokinetic profile in both 20 mg/kg and 40 mg/kg dose cohorts [2] - The Phase 2 IGNITE trial did not demonstrate beneficial effects on biomarker or clinical efficacy endpoints for ALSP patients [2] - As a result of these findings, the Phase 2 long-term extension study is being discontinued [2] Group 2: Company Perspective - The CEO of Vigil expressed gratitude towards the ALSP community for their support during the trial process, despite the disappointing data outcome [3] - The company believes that the data collected from the IGNITE trial and the ILLUMINATE natural history study have increased awareness and understanding of ALSP [3] Group 3: Trial Design and Objectives - The IGNITE trial was a global Phase 2, open-label proof-of-concept study involving 20 patients with symptomatic ALSP and a confirmed CSF1R gene mutation [4] - The primary objective was to evaluate the safety and tolerability of iluzanebart, while secondary measures included assessing its effects on target engagement and biomarkers of disease progression [4] - Patients received intravenous infusions of iluzanebart at 20 mg/kg or 40 mg/kg approximately every four weeks for one year [4] Group 4: Disease Background - ALSP is a rare, inherited neurological disease caused by a mutation in the CSF1R gene, affecting an estimated 19,000 people in the U.S. [5] - The disease typically presents in adults in their forties and is characterized by cognitive dysfunction, neuropsychiatric symptoms, and motor impairment, with a life expectancy of approximately six to seven years post-diagnosis [5] - There are currently no approved therapies for ALSP, highlighting a significant unmet medical need [5] Group 5: Company Overview - Vigil Neuroscience focuses on developing treatments for neurodegenerative diseases by restoring the function of microglia, the brain's immune cells [6] - The company is also developing VG-3927, a novel small molecule TREM2 agonist, targeting common neurodegenerative diseases, initially focusing on Alzheimer's disease [6]

Group 1 - Vigil Neuroscience, Inc. (VIGL) has recently experienced a "golden cross" event, indicating a potential bullish breakout from a technical perspective [1][2] - A golden cross occurs when a stock's short-term moving average, typically the 50-day, crosses above its long-term moving average, such as the 200-day, suggesting stronger breakouts [2] - VIGL has rallied 186.9% over the past four weeks, and it currently holds a 2 (Buy) rating on the Zacks Rank, indicating a strong potential for further gains [4] Group 2 - The bullish outlook for VIGL is supported by a positive earnings forecast, with five upward revisions in earnings estimates over the past 60 days and no downward revisions [4][6] - The combination of the positive technical indicators and the favorable earnings outlook suggests that investors should monitor VIGL for potential gains in the near future [6]

Group 1 - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1] - Vigil Neuroscience, Inc. (NASDAQ: VIGL) is under investigation regarding its proposed merger with Sanofi, which includes an upfront payment of $8.00 per share in cash [1] - The total equity value of the transaction, including a potential contingent value right (CVR) payment of $2.00 per share, is approximately $600 million on a fully diluted basis [1]

Core Viewpoint - Vigil Neuroscience, Inc. (VIGL) has seen a significant stock price increase of 340.2% over the past four weeks, closing at $7.88, with a potential upside indicated by Wall Street analysts' mean price target of $14.71, suggesting an 86.7% increase from the current price [1] Price Targets and Analyst Estimates - The mean price target is based on seven short-term estimates with a standard deviation of $4.75, indicating variability among analysts; the lowest estimate is $8 (1.5% increase), while the highest is $22 (179.2% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about VIGL's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, three earnings estimates have been revised upward, leading to a 6.9% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - VIGL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13]

Group 1: Hong Kong Stock Market - Nuclear power stocks strengthened, with China General Nuclear Power Corporation Mining rising over 8% and China General Nuclear Power Corporation increasing over 2% due to Trump's upcoming executive order aimed at simplifying reactor approval processes and strengthening fuel supply chains to promote the nuclear energy industry [1] - CRO concept stocks led the gains, as Trump's drug pricing policy is expected to benefit the domestic CXO industry, with institutions indicating a fundamental turning point has emerged; Zhaoyan New Drug surged over 11%, Tigermed rose over 10%, Kanglong Chemical increased over 6%, and WuXi AppTec gained 2% [1] - Gold stocks generally declined, with Chifeng Jilong Gold Mining and Shandong Gold falling over 3% as gold prices dropped below $3,300 [1] - Automotive stocks mostly rose, with Great Wall Motors increasing over 3%, BYD rising over 4%, Li Auto up over 4%, and Leap Motor gaining nearly 2%; the China Passenger Car Association expects retail sales of new energy vehicles to reach 980,000 units in May [1] - Country Garden saw a nearly 4% increase as over 70% of noteholders joined the restructuring support agreement [1] Group 2: US Stock Market - Vigil Neuroscience experienced a surge of over 241% following a premium acquisition by Sanofi, which announced it would acquire Vigil for $470 million in cash, potentially rising to $600 million based on future development milestones; the acquisition price represents a 236% premium over Vigil's closing price [2] - Sunrun, the largest rooftop solar company in the US, plummeted 37.05% due to the House of Representatives passing the "Beautiful Act," which significantly cuts green energy subsidies, leading to a sharp decline in the solar panel sector [2] - Fannie Mae and Freddie Mac stocks surged over 50% and 41%, respectively, following Trump's mention of privatization plans [2] - Nike's stock rose over 2% as the company plans to implement widespread price increases on products in the US market, expected to take effect as early as this week [2]